Literature DB >> 22299316

Omalizumab treatment in severe adult atopic dermatitis.

Supitchaya Thaiwat1, Atik Sangasapaviliya.   

Abstract

Atopic dermatitis (AD) is one of the most common chronic skin diseases. Treatment options include lubricants, antihistamines, and corticosteroids in either topical or oral forms. Severe AD is frequently recalcitrant to these medications. We reported three cases of severe AD patients who had elevated of IgE levels and failed to response to several prior medical treatment. After being treated with Omalizumab (humanized monoclonal anti-IgE antibody), the patients had marked alleviation of symptoms with improved Eczema Area and Severity Index (EASI) and pruritic scores. No patient experienced adverse effect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22299316

Source DB:  PubMed          Journal:  Asian Pac J Allergy Immunol        ISSN: 0125-877X            Impact factor:   2.310


  9 in total

1.  Oral administration of poly-γ-glutamate ameliorates atopic dermatitis in Nc/Nga mice by suppressing Th2-biased immune response and production of IL-17A.

Authors:  Tae-Young Lee; Doo-Jin Kim; Ji-Na Won; Il-Han Lee; Moon-Hee Sung; Haryoung Poo
Journal:  J Invest Dermatol       Date:  2013-09-11       Impact factor: 8.551

Review 2.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

3.  IgE cross-linking critically impairs human monocyte function by blocking phagocytosis.

Authors:  David M Pyle; Victoria S Yang; Rebecca S Gruchalla; J David Farrar; Michelle A Gill
Journal:  J Allergy Clin Immunol       Date:  2013-02       Impact factor: 10.793

Review 4.  Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.

Authors:  Nan Yang; Zeyu Chen; Xilin Zhang; Yuling Shi
Journal:  BioDrugs       Date:  2021-07-02       Impact factor: 5.807

Review 5.  Which Way Do We Go? Complex Interactions in Atopic Dermatitis Pathogenesis.

Authors:  Garrett J Patrick; Nathan K Archer; Lloyd S Miller
Journal:  J Invest Dermatol       Date:  2020-09-15       Impact factor: 8.551

Review 6.  Systemic Treatment of Adult Atopic Dermatitis: A Review.

Authors:  Matteo Megna; Maddalena Napolitano; Cataldo Patruno; Alessia Villani; Anna Balato; Giuseppe Monfrecola; Fabio Ayala; Nicola Balato
Journal:  Dermatol Ther (Heidelb)       Date:  2016-12-26

7.  Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome.

Authors:  Cesar Daniel Alonso-Bello; María Del Carmen Jiménez-Martínez; María Eugenia Vargas-Camaño; Sagrario Hierro-Orozco; Mario Alberto Ynga-Durand; Laura Berrón-Ruiz; Julio César Alcántara-Montiel; Leopoldo Santos-Argumedo; Diana Andrea Herrera-Sánchez; Fernando Lozano-Patiño; María Isabel Castrejón-Vázquez
Journal:  Case Reports Immunol       Date:  2019-07-04

Review 8.  Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence.

Authors:  Andreas Wollenberg; Simon Francis Thomsen; Jean-Philippe Lacour; Xavier Jaumont; Slawomir Lazarewicz
Journal:  World Allergy Organ J       Date:  2021-03-19       Impact factor: 4.084

Review 9.  Human(ized) monoclonal antibodies in atopic patients - state of the art.

Authors:  Arzu Didem Yalcin; Kevser Onbasi; Rusen Uzun; Felix Herth; Philipp Albert Schnabel
Journal:  Cent Eur J Immunol       Date:  2020-07-27       Impact factor: 2.085

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.